Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | LIPC | P11150 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4388215 | 0.90 | FAAH (0.38) | MAOBMAPK14FAAHMGLLNLRP3 | |
| SCHEMBL4388883 | 0.88 | MAOB (0.37) | MAOBMAPK14FAAHMGLLNLRP3 | |
| SCHEMBL4380922 | 0.82 | FAAH (0.41) | FAAHMGLLBCHELIPCACHE | |
| SCHEMBL4386011 | 0.81 | KDM4C (0.34) | MAOBMAPK14FAAHMGLLPTGER1 | |
| SCHEMBL4380795 | 0.78 | FAAH (0.38) | MAOBMAPK14FAAHMGLLBCHE | |
| SCHEMBL4385063 | 0.77 | MAPK14 (0.39) | MAOBMAPK14 | |
| SCHEMBL4384187 | 0.76 | FAAH (0.36) | MAOBFAAHMGLLNLRP3BCHE | |
| SCHEMBL4387544 | 0.71 | KDM4C (0.33) | MAOBPTGER1TRPA1 | |
| SCHEMBL4396461 | 0.71 | SLC26A3 (0.43) | MAPK14PTGER1 | |
| SCHEMBL4379399 | 0.69 | ALDH1A1 (0.44) | MAPK14KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | MAOB 3920/4885MAPK14 1693/4885FAAH 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.